



To: European Society of Gynecological Oncology - ESGO

Direct dial

Fax number

Internal postal address NG-532

E-mail r.nout@erasmusmc.nl

Our reference Secr/JJ/

Date September 5, 2022

Re: ESGO Council Elections 2024

Rotterdam, September 10th, 2023

Postal address

P.O. box 2040
3000 CA Rotterdam, NL

Visiting address

Dr. Molewaterplein 40
3015 GD Rotterdam, NL

Contact & route

www.erasmusmc.nl

Afdelingshoofd

Prof. dr. R.A. Nout

Waarnemend afdelingshoofd

Prof. dr. L. Incrocci

Medische Staf

Dr. H. Abusaris
Dr. M.H.A. Baaijens
Dr. I.E. Antonisse
Drs. R. de Boer
Dr. M.E.M.C. Christianen
Dr. M. Franckena
Prof. dr. L. Incrocci
Drs. P.P. Jansen
Drs. F. Keskin-Cambay
Dr. A.M. Mendez Romero
Drs. J.W.M. Mens
Drs. C.P.M. Mulder-Janus
Dr. J.J.M.E. Nuytens
Dr. M.J.J. Olofsen van Acht
Drs. M. van de Pol
Drs. J.O. Praag
Drs. I.M.N. de Pree
Drs. C.M. van Rij
Dr. G.A. Sattler
Drs. A. Schoonbeek
Drs. C. Slagter
Drs. A.T. Swaak-Kragten
Drs. L. Tans
Drs. M.Z. Toet-Bosma
Drs. G.M. Verduijn
Drs. K.C. de Vries
Dr. C.M.A. van Zwiennen

Dear ESGO council,

During my career as radiation oncologist I have committed myself to improve the outcomes for women with gynecological cancer. This motivation rose from both a long term clinical management and follow-up of these women and being part of practice changing research. I believe this is best achieved in close multidisciplinary team work, and that has also motivated me take on active roles in collaboration with gynecological oncology societies. Apart from direct clinical care, I pursue this goal through initiation and participation in clinical research; clinical implementation of treatment innovations; dissemination of knowledge through educational activities and taking part in guideline committees.

Over the last years it has been a great pleasure to actively collaborate with ESGO as representative of ESTRO in multidisciplinary management guidelines for the treatment of women with endometrial, cervical and most recently vaginal cancer. This brings great awareness to the differences in clinical practice from country to country in Europe and beyond, which necessitates also a balanced approach to ensure its applicability. In addition we successfully initiated a joint course for multidisciplinary management of cervical cancer, which was motivated through discussions in the guideline committee. An important aspect of this course is the multidisciplinary approach, bringing in multidisciplinary teams.

Currently I am active in different international societies which can help in achieving ESGO's mission, such as educational and guideline activities. Within ESTRO I'm co-leading the initiation of the gynecological cancer focus group, and co-director of the ESTRO teaching course for gynecological cancer. Being born and spending my childhood in Africa has always motivated me to devote my energy also to global causes. This has mainly been as part of several educational activities focusing on the management of cervical cancer in lower middle income countries. More recently I pursue this also through a focus on research in my role as co-chair of GCIG-CCRN.

It is therefore a great pleasure to put myself forward as candidate for a council position as radiation oncologist, a position through which I believe I can effectively contribute to the team and mission of ESGO.

Yours sincerely,

A handwritten signature in blue ink, consisting of a vertical line on the left, a horizontal line crossing it, and a long diagonal line extending to the right.

Prof. dr. Remi A. Nout
Head of the Department of Radiotherapy

R.A. Nout – Curriculum Vitae

Department of Radiotherapy
Erasmus Medical Center – Erasmus University
P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

Phone +31 (0)10 7041366
fax +31 (0)10 7041013
e-mail: r.nout@erasmusmc.nl

Personal information:

Family name: Nout
First names: Remi Abubakar
Date of birth: January 14, 1975
Nationality: Netherlands

Degrees:

April 2020: Professor of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
April 2013: PhD. with distinction (i.e. cum laude)
Title: 'PORTEC: Postoperative Radiation Therapy for Endometrial Carcinoma – reducing overtreatment and improving quality of life'.
November 2008: Radiation Oncologist
Board (KNMG) certified since November 1st, 2013
Re-certified September 2018 valid thru 2023
February 2000: Medical Doctor (Arts-examen), University of Maastricht
BIG registration number: 19052256901
July 1997: Master in Medicine (Doctoraal), University of Maastricht

Professional experience:

Okt 2019 – present: Professor and Head of the department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands.
Sept 2016 – 2019: Visiting professor at the department of Radiation Oncology of the Medical University of Vienna, Allgemeines Krankenhaus Wien, prof. dr. R. Pötter
Nov 2008 – Sept 2019: Radiation Oncologist, Leiden University Medical Center (LUMC). Special interests: brachytherapy, gynaecological oncology, rectal cancer.
Clinical projects: implementation of image guided brachytherapy for gynaecological cancer; implementation of IGRT for gynaecological cancer; image guided brachytherapy for rectal cancer.
Mar 2014 – Sept 2016: Dutch Cancer Society Clinical fellowship 'Image guided brachytherapy' KWF: UL 2013-5891. <http://www.fightcancer.nl/over-kanker/onderzoekers/remi-nout>
March – September 2014: Dept of Radiation Oncology, Jewish General Hospital, McGill University, Montreal Canada. January – May 2015 Dept of Oncology, Aarhus University Hospital, Aarhus, Denmark. June – November 2015 Dept of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. December 2015 – May 2016, Dept of Radiation Oncology, Daniel den Hoed Kliniek, Erasmus Medical Center, Rotterdam, the Netherlands.
Nov. 2003 – Nov 2008: Resident in Radiation Oncology, Leiden University Medical Center.

Activities in professional societies

2022 – present: Co-Chair Gynecological Cancer Inter Group (GCIG) – Cervical Cancer Research Network (CCRN).
2018 – present: Treasurer and since 2021 Chair of the Dutch Gynaecological Oncology Group (DGOG).
2016 – present: Faculty and since 2021 co-director of European Society of Radiotherapy and Oncology (ESTRO) – course radiotherapy for gynaecological cancers

- 2016 – present: Radiation representative education committee activities, past representative in the council of the International Gynecological Cancer Society (IGCS)
- 2016 – 2022: Chair of the Dutch Platform for Radiotherapy of Gynaecological Malignancies (LPRGT)
- 2018: ESTRO representative in ESGO examination committee for European Society of Gynaecological Oncology (ESGO) curriculum

Key publications:

Nout RA, Calaminus G, Planchamp F, Chargari C, Lax S, Martelli H, McCluggage WG, Morice P, Pakiz M, Schmid MP, Stunt J, Timmermann B, Vokuhl C, Orbach D, Fotopoulou C. ESTRO/ESGO/SIOPE Guidelines for the management of patients with vaginal cancer. *Int J Gynecol Cancer*. 2023 Aug 7;33(8):1185-1202.

Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, Fischerová D, Jahnn-Kuch D, Joly F, Kohler C, Lax S, Lorusso D, Mahantshetty U, Mathevet P, Naik R, **Nout RA**, Oaknin A, Peccatori F, Persson J, Querleu D, Bernabé SR, Schmid MP, Stepanyan A, Svintsitskyi V, Tamussino K, Zapardiel I, Lindegaard J. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. *Int J Gynecol Cancer*. 2023 May 1;33(5):649-666.

Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, **Nout RA**, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer*. 2021 Jan;31(1):12-39.

Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, **Nout RA**; EMBRACE Collaborative Group. Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. *Int J Radiat Oncol Biol Phys*. 2016 Apr 1;94(5):1088-98.

R.A. Nout, V.T. Smit, H. Putter, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C.H.M. Lutgens, E.M. van der Steen-Banasik, J.W. Mens, A. Slot, M.C. Stenfert Kroese, B.N. van Bunningen, A.C. Ansink, W.L. van Putten, C.L. Creutzberg, for the PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet* 2010; 375: 816-23.

R.A. Nout, H. Putter, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C.H.M. Lutgens, E.M. van der Steen-Banasik, J.W. Mens, A. Slot, V.T. Smit, C.L. Creutzberg. Quality of life after radiotherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. *J Clin Oncol*. 2009 Jul 20;27(21):3547-56.

Remi A. Nout, Lonneke V. van de Poll-Franse, Marnix L.M. Lybeert, Carla C. Wárlám-Rodenhuis, Jan J. Jobsen, Jan Willem M. Mens, Ludy C.H.W. Lutgens, Betty Pras, Wim L.J. van Putten, and Carien L. Creutzberg, for the PORTEC Study Group. Long-term Outcome and Quality of Life of Endometrial Cancer Patients Treated With or Without Pelvic Radiotherapy in the PORTEC-1 Trial. *J Clin Oncol*. 2011;29:1692-1700.